Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial
Topic starter 22/07/2022 6:09 pm
"In this G47∆ phase 2 trial, the median OS was 28.8 months from the initial surgery."
22/07/2022 9:39 pm
Topic starter 22/07/2022 10:09 pm
Yes, definitely a big step forward!